Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5994556 | 0.81 | FDPS (0.37) | FDPSPDE3A | |
| SCHEMBL5995956 | 0.81 | FDPS (0.37) | FDPSPDE3A | |
| SCHEMBL7862907 | 0.79 | FDPS (0.47) | FDPSPDE3A | |
| SCHEMBL7855065 | 0.76 | FDPS (0.40) | FDPSPDE3A | |
| SCHEMBL7861872 | 0.76 | FDPS (0.40) | FDPSPDE3A | |
| SCHEMBL3728830 | 0.74 | FDPS (0.38) | FDPSPDE3A | |
| SCHEMBL7862915 | 0.72 | FDPS (0.40) | FDPSPDE3A | |
| SCHEMBL7861919 | 0.72 | FDPS (0.40) | FDPSPDE3A | |
| SCHEMBL5995945 | 0.71 | FDPS (0.41) | FDPSPDE3A | |
| SCHEMBL3735502 | 0.71 | FDPS (0.41) | FDPSPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| EP-1121366-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 2001-08-08 | — | — | EP | disclosed |
| WO-1999051613-A1 | PRODRUGS OF PHOSPHOROUS-CONTAINING PHARMACEUTICALS | MEDIVIR AB (SE) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | FDPS 304/4885PDE3A 1375/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | FDPS 612/4885PDE3A 2205/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | FDPS 304/4885PDE3A 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.